Jerome D. Jabbour - 30 Apr 2025 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Reporting relationship: President and CEO, Director
Issuer ticker: MTNB
Reported as of: 30 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 May 2025, 17:19:46 UTC
Prior SEC filing: 15 Dec 2023
Next SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Keith A. Kucinski, attorney-in fact for Jerome D. Jabbour

Key filing fact

Jerome D. Jabbour filed Form 4 for Matinas BioPharma Holdings, Inc. (MTNB) on 02 May 2025.

Key facts

This page summarizes Jerome D. Jabbour's Form 4 filing for Matinas BioPharma Holdings, Inc. (MTNB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 May 2025, 17:19.

Change

Previous filing in this sequence was filed on 15 Dec 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001698838 Primary reporting owner

Jabbour Jerome D

Relationship: President and CEO, Director
Address: C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER
Signature: /s/ Keith A. Kucinski, attorney-in fact for Jerome D. Jabbour
Signature date: 02 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTNB transaction Derivative

Stock Option (right to Buy)

Award

Transaction value: $0
Shares: +70,100
Change %
Price: $0.000000
Shares after: 70,100
Date: 30 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,100
Exercise price: $0.5900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option award was made subject to the approval of, and in accordance with the terms of, the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"), which will be voted on at the Issuer's 2025 annual meeting of stockholders to be held on June 23, 2025. The options vest, subject to stockholder approval of the 2025 Plan, as to 25% of the shares on April 30, 2026 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing April 30, 2026.